Why Did Peptide Sciences Shut Down? Timeline, FDA Pressure, and What It Means for the Industry
Peptide Sciences, the largest gray-market research peptide vendor in the U.S., voluntarily shut down on March 6, 2026. A breakdown of the FDA enforcement actions, pharmaceutical lawsuits, and new legislation that led to the closure.
Read Full ArticleAll News
Medicare and Insurance Coverage for Peptide Therapy in 2026
Does insurance cover peptide therapy? Medicare and private insurance coverage for peptides depends on FDA approval status, medical necessity, and specific plan policies. This comprehensive guide explains when peptides are covered and how to maximize reimbursement.
EU Peptide Regulations: Country Guide
Overview of the Regulatory Action The European Union presents a complex regulatory landscape for peptides, differing significantly from the more unified approach observed in the United States under the FDA.
AKS Claims Allowed in D. Nev. Compounding Pharmacy Fraud Case
AKS Claims Proceed Against Compounding Pharmacy Accused of Kickbacks In a significant development for the pharmaceutical industry, a federal court in Nevada has ruled that claims under the Anti-Kickback Statute (AKS) can proceed against a compounding pharmacy accused of engaging in illegal kickback...
Health Law Alliance Appoints Dr. Martha Rumore as Of Counsel
Health Law Alliance Welcomes Compounding Expert Pharmacist-Attorney Dr. Martha Rumore as Of Counsel The Health Law Alliance has announced the appointment of Dr. Martha Rumore, a noted expert in pharmaceutical compounding and a licensed attorney, as Of Counsel.
Compounding Pharmacy Sues Lilly, Novo for GLP-1 Drug Monopoly
Lilly, Novo Sued Over GLP-1 Drug Dominance by Compounding Pharmacy In a significant legal development, pharmaceutical giants Eli Lilly and Novo Nordisk are facing a lawsuit from a compounding pharmacy that accuses them of monopolistic practices in the market for GLP-1 receptor agonists, a class of ...
Telehealth Exclusivity Wars Heat Up: GLP-1 Compounder Lawsuit
GLP-1 Compounder Lawsuit Highlights Telehealth Exclusivity Wars In a significant legal development affecting the peptide industry, a lawsuit involving a compounding pharmacy that produces GLP-1 (glucagon-like peptide-1) medications has brought to light the escalating competition over telehealth exc...
Telemedicine Peptide Clinics Face New Compliance Requirements
In the evolving landscape of healthcare, telemedicine has emerged as a pivotal component, offering patients unprecedented access to medical services.
Major Peptide Supplier Faces Regulatory Action: Industry Impact
The peptide industry, a cornerstone of modern biomedical research and therapeutic development, is experiencing a seismic shift as one of its major suppliers faces significant regulatory action.
International Peptide Regulations: How US Laws Compare
In the rapidly evolving world of biotechnology and pharmaceuticals, peptides are gaining unprecedented attention due to their potential in treating a range of conditions from metabolic disorders to cancer.
Peptide Market Shifts as Regulatory Pressure Increases
The peptide market, a cornerstone of modern pharmaceutical innovation, is experiencing a seismic shift as regulatory pressures intensify globally.
Compounding Pharmacy Industry Responds to GLP-1 Regulations
The compounding pharmacy industry is currently navigating a complex regulatory landscape, especially in light of recent changes to the guidelines surrounding the compounding of GLP-1 (glucagon-like peptide-1) receptor agonists.
Insurance Coverage for Peptide Therapy: Legal and Policy Updates
In recent years, peptide therapy has emerged as a promising treatment option in various medical fields, including endocrinology, dermatology, and neurology.